NDA 021842 · Takeda Pharms USA
Actoplus Met
Metformin Hydrochloride, Pioglitazone Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Aug 29, 2005
Approved uses
3
Original approval plus efficacy supplements
Registered trials
2,828
753 Phase 3, 150 recruiting
FAERS reports
1,268
788 serious, 117 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CONGESTIVE HEART FAILURE and LACTIC ACIDOSIS Congestive Heart Failure Thiazolidinediones, including pioglitazone, which is a component of ACTOPLUS MET ® , cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1) ] . After initiation of ACTOPLUS MET, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If congestive heart failure develops while taking ACTOPLUS MET, consider discontinuation of ACTOPLUS MET or dosage reduction of pioglitazone in ACTOPLUS MET [see Warnings and Precautions (5.1) ] . ACTOPLUS MET is not recommended in patients with symptomatic heart failure [see Warnings and Precautions (5.1) ] . Initiation of ACTOPLUS MET in patients with established New York Heart Association (NYHA) Class III or IV heart failure is...
What it is approved for
From the label in effect Aug 21, 2026.
ACTOPLUS MET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use ACTOPLUS MET is not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis. ACTOPLUS MET is a combination of pioglitazone, a thiazolidinedione agonist of peroxisome proliferator receptor gamma, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1 )
Mechanism: ACTOPLUS MET combines two antihyperglycemic agents: pioglitazone and metformin. Pioglitazone Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2016 Supplement 20 · Efficacy LetterLabel
- May 17, 2012 Supplement 10 · Efficacy LetterLabel
- Aug 29, 2005 Original approval · Type 4 - New Combination LabelReviewOther Important Information from FDA
2 products under this application
- ACTOPLUS MET · METFORMIN HYDROCHLORIDE 500MG; PIOGLITAZONE HYDROCHLORIDE EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- ACTOPLUS MET · METFORMIN HYDROCHLORIDE 850MG; PIOGLITAZONE HYDROCHLORIDE EQ 15MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Metformin" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- ACTIV-6: COVID-19 Study of Repurposed MedicationsPivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT04885530 · 10,956 participants · Start Jun 8, 2021 · Primary completion Apr 29, 2024
Drug: Ivermectin; Fluvoxamine and 3 more · For: Covid19
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 110 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
Juliana CN ChanAcademic, hospital or other
NCT06693934 · 9,000 participants (planned) · Start Nov 23, 2024 · Primary completion Oct 2027
Drug: Medication · For: Diabetes; Pre Diabetes; Hypertension and 2 more
Sites: Hong Kong, Hong Kong
- Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive SubjectsPivotal-lookingStatus unknown
Ramathibodi HospitalAcademic, hospital or other
NCT01364675 · 8,900 participants (planned) · Start Jan 2012 · Primary completion Jul 2016
Drug: Metformin+Enalapril+Simvastatin; Placebo tablet · For: Pre-diabetes; Pre-hypertension
Sites: Muang District, Thailand
- Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomesPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT02915198 · 7,410 participants (planned) · Start Apr 3, 2023 · Primary completion Sep 28, 2029
Drug: Metformin XR; Placebo · For: Prediabetic State; Atherosclerosis; Metformin
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 40 sites in all
- A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)Pivotal-lookingRecruiting
Kyu Chang WonAcademic, hospital or other
NCT06627322 · 5,950 participants (planned) · Start Nov 21, 2024 · Primary completion Sep 30, 2029
Drug: Dual-combination therapy; Triple-combination therapy · For: Type 2 Diabetes
Sites: Daegu, South Korea; Seoul, South Korea
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01709305 · 5,570 participants · Start Nov 8, 2012 · Primary completion Apr 17, 2015
Drug: Metformin; Sitagliptin and 4 more · For: Type 2 Diabetes Mellitus
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- bladder cancer299
- blood glucose increased109
- nausea97
- weight decreased81
- death53
- flushing52
- blood glucose decreased45
- dizziness44
- drug ineffective41
- dyspnoea40
- asthenia39
- fatigue39
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 135 |
| 2007 | 76 |
| 2008 | 42 |
| 2009 | 97 |
| 2010 | 106 |
| 2011 | 100 |
| 2012 | 94 |
| 2013 | 44 |
| 2014 | 30 |
| 2015 | 325 |
| 2016 | 78 |
| 2017 | 28 |
| 2018 | 30 |
| 2019 | 34 |
| 2020 | 20 |
| 2021 | 6 |
| 2022 | 6 |
| 2023 | 7 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Actoplus Met (Pioglitazone HCl/Metformin HCl)
2024 spending
$112K
Beneficiaries
21
119 claims
Per beneficiary
$5,326
$9.53 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $312,106 |
| 2021 | $203,504 |
| 2022 | $140,809 |
| 2023 | $131,485 |
| 2024 | $111,841 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Greff D, Juhász AE, Váncsa S, et al. · Reprod Biol Endocrinol 2023 · Meta-Analysis, Systematic Review
- Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M, Coppola A, Sesa V, et al. · World J Gastroenterol 2024 · Meta-Analysis, Systematic Review
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Tsapas A, Avgerinos I, Karagiannis T, et al. · Ann Intern Med 2020 · Comparative Study, Research Support, Non-U.S. Gov't
- Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.
Melin J, Forslund M, Alesi S, et al. · J Clin Endocrinol Metab 2024 · Meta-Analysis, Systematic Review
- Safety of metformin in chronic kidney disease and type 2 diabetes mellitus: a systematic review and meta-analysis.
Patiño-Cardona S, Pascual-Morena C, Sequí-Domínguez I, et al. · Eur J Pharmacol 2026 · Systematic Review, Meta-Analysis
- Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials.
Nabrdalik K, Skonieczna-Żydecka K, Irlik K, et al. · Front Endocrinol (Lausanne) 2022 · Meta-Analysis, Systematic Review
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.